Potassium citrate

Description

Potassium citrate extended-release tablets are a citrate salt of potassium, formulated for oral administration. The empirical formula is K₃C₆H₅O₇ • H₂O, and the chemical structure is represented accordingly. These tablets are characterized as off white to tan yellowish, wax-matrix formulations, available in three strengths: 5 mEq (540 mg), 10 mEq (1080 mg), and 15 mEq (1620 mg) of potassium citrate. Inactive ingredients include carnauba wax, silicon dioxide, and magnesium stearate. It is important to note that the FDA-approved dissolution test specifications for this formulation differ from those established by the USP.

Uses and Indications

Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) associated with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis, with or without calcium stones.

There are no teratogenic or nonteratogenic effects associated with the use of this medication.

Dosage and Administration

For patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq per day. This can be administered as 30 mEq two times per day or 20 mEq three times per day. Doses should be taken with meals or within 30 minutes after meals, including a bedtime snack.

In cases of mild to moderate hypocitraturia (urinary citrate > 150 mg/day), therapy should commence at a dosage of 30 mEq per day. This may be given as 15 mEq two times per day or 10 mEq three times per day, also with meals or within 30 minutes after meals, including a bedtime snack.

Healthcare professionals should ensure that patients adhere to the specified timing of administration to optimize therapeutic outcomes.

Contraindications

Use of this product is contraindicated in the following situations:

Patients with hyperkalemia or conditions predisposing to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown, due to the risk of exacerbating elevated potassium levels.

Patients with gastrointestinal conditions that may cause arrest or delay in tablet passage, such as delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture, as these conditions may hinder proper absorption.

Patients with peptic ulcer disease, as the product may exacerbate gastrointestinal irritation.

Patients with active urinary tract infections, due to the potential for worsening the infection.

Patients with renal insufficiency, specifically those with a glomerular filtration rate of less than 0.7 ml/kg/min, as this may lead to accumulation of the product and increased risk of adverse effects.

Warnings and Precautions

Patients receiving potassium citrate must be closely monitored for the development of hyperkalemia, particularly in those with compromised renal function or conditions that impair potassium excretion, such as severe myocardial damage or heart failure. Hyperkalemia can manifest rapidly and may be asymptomatic, leading to potentially fatal cardiac arrest. Therefore, the administration of potassium citrate in patients with chronic renal failure or similar conditions is contraindicated (5.1).

In addition, if patients experience severe vomiting, abdominal pain, or gastrointestinal bleeding, potassium citrate should be discontinued immediately. It is essential to investigate the possibility of bowel perforation or obstruction in such cases (5.2).

Healthcare professionals are advised to remain vigilant for these adverse effects and to ensure appropriate monitoring and intervention as necessary.

Side Effects

Patients may experience a range of adverse reactions associated with potassium citrate administration. Common adverse reactions include minor gastrointestinal complaints such as abdominal discomfort, vomiting, diarrhea, loose bowel movements, and nausea.

Serious adverse reactions can occur, particularly in patients with impaired mechanisms for excreting potassium. Hyperkalemia is a significant concern, as it can lead to cardiac arrest. This condition may develop rapidly and can be asymptomatic, making it potentially fatal. Therefore, the use of potassium citrate is contraindicated in patients with chronic renal failure or any other conditions that impair potassium excretion, such as severe myocardial damage or heart failure.

Additionally, gastrointestinal lesions may arise, necessitating immediate discontinuation of potassium citrate if patients present with severe vomiting, abdominal pain, or gastrointestinal bleeding. In such cases, the possibility of bowel perforation or obstruction should be thoroughly investigated.

Other important considerations include the risk of hyperkalemia in patients with predisposing conditions, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, or extensive tissue breakdown. Caution is also advised for patients who may experience delays in tablet passage through the gastrointestinal tract, including those with delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture. Furthermore, potassium citrate should be avoided in patients with peptic ulcer disease, active urinary tract infections, or renal insufficiency characterized by a glomerular filtration rate of less than 0.7 ml/kg/min.

Drug Interactions

Concomitant administration of potassium-sparing diuretics is contraindicated due to the potential for severe hyperkalemia. It is advised to avoid the use of these agents together.

Drugs that slow gastrointestinal transit time, including anticholinergics, may exacerbate gastrointestinal irritation associated with potassium salts. Caution is recommended when these agents are used concurrently.

For patients receiving renin-angiotensin-aldosterone inhibitors, monitoring for hyperkalemia is essential. Regular assessment of potassium levels is advised to prevent complications.

Nonsteroidal anti-inflammatory drugs (NSAIDs) may also increase the risk of hyperkalemia. It is important to monitor potassium levels in patients taking NSAIDs alongside other medications that can elevate potassium.

Packaging & NDC

The table below lists all NDC Code configurations of Potassium Citrate, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Therefore, the use of this medication in children is not recommended until further data is available to support its use in this population.

Geriatric Use

Elderly patients may not have specific information available regarding the use of this medication, including dosage adjustments or safety concerns. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients should be aware that animal reproduction studies have not been conducted with potassium citrate. Therefore, it is not known whether potassium citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Given the lack of data, potassium citrate should be prescribed to pregnant women only if clearly needed, weighing the potential benefits against any unknown risks. Healthcare professionals are advised to exercise caution and consider alternative treatments when appropriate.

Lactation

Potassium citrate is not known to affect the normal potassium ion content of human milk, which is approximately 13 mEq/L. However, due to the lack of specific data regarding its excretion in breast milk and potential effects on breastfed infants, potassium citrate should be administered to lactating mothers only if clearly needed.

Renal Impairment

Patients with impaired mechanisms for excreting potassium are at an increased risk of hyperkalemia when administered potassium citrate. This condition can lead to cardiac arrest and may develop rapidly, often without symptoms. Therefore, the use of potassium citrate is contraindicated in patients with chronic renal failure or any other conditions that impair potassium excretion, such as severe myocardial damage or heart failure. Careful consideration and monitoring are essential in these populations to prevent potentially fatal outcomes.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of data does not preclude the need for careful evaluation and monitoring based on individual patient circumstances.

Overdosage

The administration of potassium salts in individuals without predisposing conditions for hyperkalemia is unlikely to result in serious hyperkalemia when dosages are kept within recommended limits. However, it is crucial to recognize that hyperkalemia is often asymptomatic, typically identified only through elevated serum potassium levels and specific electrocardiographic changes. These changes may include T-wave peaking, loss of the P-wave, S-T segment depression, and QT interval prolongation.

Late manifestations of hyperkalemia can be severe, potentially leading to muscle paralysis and cardiovascular collapse due to cardiac arrest. Therefore, prompt recognition and management of hyperkalemia are essential.

Management of Hyperkalemia

In the event of suspected hyperkalemia, the following treatment measures should be implemented:

1. Monitoring: Patients should be closely monitored for arrhythmias and electrolyte imbalances.

2. Medication Review: Discontinue any medications containing potassium or those with potassium-sparing properties. This includes potassium-sparing diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain nutritional supplements.

3. Dietary Restrictions: Eliminate foods high in potassium from the patient's diet. Common high-potassium foods include almonds, apricots, bananas, various beans (lima, pinto, white), cantaloupe, canned carrot juice, figs, grapefruit juice, halibut, milk, oat bran, potatoes (with skin), salmon, spinach, and tuna.

4. Calcium Administration: Administer intravenous calcium gluconate if the patient is at low risk for digitalis toxicity.

5. Insulin and Dextrose: Administer an intravenous solution of 10% dextrose containing 10-20 units of crystalline insulin per 1,000 mL at a rate of 300-500 mL/hr.

6. Correction of Acidosis: If acidosis is present, correct it with intravenous sodium bicarbonate.

7. Dialysis: Consider hemodialysis or peritoneal dialysis for severe cases.

8. Use of Exchange Resins: While exchange resins may be utilized, they should not be relied upon as the sole treatment for acute hyperkalemia.

It is important to note that lowering potassium levels too rapidly in patients taking digitalis can precipitate digitalis toxicity. Additionally, in patients with impaired potassium excretion mechanisms, such as those with chronic renal failure or severe myocardial damage, the administration of potassium citrate can lead to hyperkalemia and potentially fatal cardiac arrest. Therefore, potassium citrate should be avoided in these populations.

In cases where gastrointestinal symptoms such as severe vomiting, abdominal pain, or gastrointestinal bleeding occur, potassium citrate should be discontinued immediately, and further investigation for possible bowel perforation or obstruction should be conducted.

Nonclinical Toxicology

Animal reproduction studies have not been conducted to evaluate the teratogenic potential of potassium citrate. Therefore, it remains unknown whether potassium citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Potassium citrate should be administered to pregnant women only if clearly needed.

Regarding non-teratogenic effects, the normal potassium ion concentration in human milk is approximately 13 mEq/L. The impact of potassium citrate on this concentration is not established. Consequently, potassium citrate should be given to breastfeeding women only if clearly needed.

No specific details are available regarding nonclinical toxicology or animal pharmacology and toxicology in the provided insert.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Advise patients to take each dose of the medication without crushing, chewing, or sucking the tablet to ensure proper absorption and effectiveness. It is important for patients to take this medicine only as directed, particularly if they are also using diuretics and digitalis preparations, as this can affect their treatment regimen.

Patients should be instructed to consult their doctor if they experience any difficulty swallowing the tablets or if they feel that the tablet is sticking in their throat. Additionally, patients must be made aware of the importance of reporting any signs of gastrointestinal bleeding, such as tarry stools, to their doctor immediately.

Inform patients that their healthcare provider will conduct regular blood tests and electrocardiograms to monitor their safety while on this medication. This ongoing assessment is crucial for ensuring the patient's well-being during treatment.

Storage and Handling

The product is supplied in a tight container to ensure stability and integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). Proper storage conditions are essential to maintain the product's efficacy and safety.

Additional Clinical Information

No further data are available.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Potassium Citrate as submitted by XLCare Pharmaceuticals, Inc.. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)